71 related articles for article (PubMed ID: 24413201)
1. Selected factors of fibrinolysis in the Buerger's disease.
Terlecki P; Feldo M; Przywara S; Iłżecki M; Kęsik JJ; Borowski G; Wroński J; Zubilewicz T
Pol Przegl Chir; 2013 Nov; 85(11):630-7. PubMed ID: 24413201
[TBL] [Abstract][Full Text] [Related]
2. Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Hus I; Sokolowska B; Walter-Croneck A; Chrapko M; Nowaczynska A; Dmoszynska A
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):133-9. PubMed ID: 23358197
[TBL] [Abstract][Full Text] [Related]
3. Vascular function and circulating progenitor cells in thromboangitis obliterans (Buerger's disease) and atherosclerosis obliterans.
Idei N; Nishioka K; Soga J; Hidaka T; Hata T; Fujii Y; Fujimura N; Maruhashi T; Mikami S; Teragawa H; Kihara Y; Noma K; Chayama K; Higashi Y
Hypertension; 2011 Jan; 57(1):70-8. PubMed ID: 21115876
[TBL] [Abstract][Full Text] [Related]
4. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
5. An Iranian scoring system for diagnosing Buerger's disease.
Ramin M; Salimi J; Meysamie A
Acta Med Iran; 2014 Feb; 52(1):60-5. PubMed ID: 24658990
[TBL] [Abstract][Full Text] [Related]
6. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
7. Autonomic functions in Buerger's disease.
Singh K; Sood S
Indian J Physiol Pharmacol; 2001 Oct; 45(4):470-4. PubMed ID: 11883155
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical properties in the patients with Buerger's disease--possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture.
Sato T; Tamai H; Kobayashi M; Yamamoto K; Komori K
Cardiovasc Pathol; 2011; 20(5):266-71. PubMed ID: 20708412
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
11. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease).
Makita S; Nakamura M; Murakami H; Komoda K; Kawazoe K; Hiramori K
Circulation; 1996 Nov; 94(9 Suppl):II211-5. PubMed ID: 8901748
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex.
Papa M; Bass A; Adar R; Halperin Z; Schneiderman J; Becker CG; Brautbar H; Mozes E
Surgery; 1992 May; 111(5):527-31. PubMed ID: 1598672
[TBL] [Abstract][Full Text] [Related]
13. Microcirculatory characteristics in patients with Buerger's disease.
Nishikimi N; Sakurai T; Shionoya S; Oshima M
Angiology; 1992 Apr; 43(4):312-9. PubMed ID: 1558316
[TBL] [Abstract][Full Text] [Related]
14. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes.
Edo N; Miyai K; Ogata S; Nakanishi K; Hiroi S; Tominaga S; Aiko S; Kawai T
Cardiovasc Pathol; 2010; 19(1):59-62. PubMed ID: 19135391
[TBL] [Abstract][Full Text] [Related]
15. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
[TBL] [Abstract][Full Text] [Related]
16. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger's disease).
Park HS; Cho KH; Kim KL; Kim DK; Lee T
Vasc Med; 2013 Dec; 18(6):331-9. PubMed ID: 24292638
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
18. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame?
Fazeli B; Rezaee SA
Vascular; 2011 Jun; 19(3):141-53. PubMed ID: 21652666
[TBL] [Abstract][Full Text] [Related]
19. Alteration of the fibrinolytic system in patients with peripheral arterial occlusive disease.
Poredos P; Stegnar M; Gacnik A
Vasa; 1999 May; 28(2):106-11. PubMed ID: 10409921
[TBL] [Abstract][Full Text] [Related]
20. [Verification of the diagnosis of Buerger's disease in outpatients].
Cnotliwy M; Gasińska M; Bogucki W; Gutowski P; Sych Z
Wiad Lek; 2001; 54(7-8):375-9. PubMed ID: 11641891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
